Nxera Pharma Statistics
Total Valuation
Nxera Pharma has a market cap or net worth of 574.55 million. The enterprise value is 794.02 million.
| Market Cap | 574.55M |
| Enterprise Value | 794.02M |
Important Dates
The next estimated earnings date is Thursday, August 7, 2025.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 89.90M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +6.46% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 73.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.79 |
| PB Ratio | 1.28 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -51.32 |
| EV / Sales | 3.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -21.66 |
Financial Position
The company has a current ratio of 3.72, with a Debt / Equity ratio of 0.99.
| Current Ratio | 3.72 |
| Quick Ratio | 2.83 |
| Debt / Equity | 0.99 |
| Debt / EBITDA | n/a |
| Debt / FCF | -12.07 |
| Interest Coverage | -5.36 |
Financial Efficiency
Return on equity (ROE) is -3.49% and return on invested capital (ROIC) is -2.09%.
| Return on Equity (ROE) | -3.49% |
| Return on Assets (ROA) | -1.90% |
| Return on Invested Capital (ROIC) | -2.09% |
| Return on Capital Employed (ROCE) | -3.46% |
| Revenue Per Employee | 532,643 |
| Profits Per Employee | -39,981 |
| Employee Count | 374 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 1.48 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.21% in the last 52 weeks. The beta is 0.31, so Nxera Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | -25.21% |
| 50-Day Moving Average | 5.96 |
| 200-Day Moving Average | 7.12 |
| Relative Strength Index (RSI) | 83.48 |
| Average Volume (20 Days) | 86 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nxera Pharma had revenue of 206.13 million and -15.47 million in losses. Loss per share was -0.17.
| Revenue | 206.13M |
| Gross Profit | 152.44M |
| Operating Income | -30.32M |
| Pretax Income | -26.86M |
| Net Income | -15.47M |
| EBITDA | -3.05M |
| EBIT | -30.32M |
| Loss Per Share | -0.17 |
Balance Sheet
The company has 230.15 million in cash and 442.50 million in debt, giving a net cash position of -212.35 million.
| Cash & Cash Equivalents | 230.15M |
| Total Debt | 442.50M |
| Net Cash | -212.35M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 447.89M |
| Book Value Per Share | 4.98 |
| Working Capital | 259.79M |
Cash Flow
In the last 12 months, operating cash flow was -32.72 million and capital expenditures -3.93 million, giving a free cash flow of -36.65 million.
| Operating Cash Flow | -32.72M |
| Capital Expenditures | -3.93M |
| Free Cash Flow | -36.65M |
| FCF Per Share | n/a |
Margins
Gross margin is 73.95%, with operating and profit margins of -14.71% and -7.51%.
| Gross Margin | 73.95% |
| Operating Margin | -14.71% |
| Pretax Margin | -13.03% |
| Profit Margin | -7.51% |
| EBITDA Margin | -1.48% |
| EBIT Margin | -14.71% |
| FCF Margin | n/a |
Dividends & Yields
Nxera Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.46% |
| Shareholder Yield | n/a |
| Earnings Yield | -2.69% |
| FCF Yield | -6.38% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nxera Pharma has an Altman Z-Score of 1.1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.1 |
| Piotroski F-Score | n/a |